MedTrace Logo

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

NCT02425644 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1133

Last updated 2025-03-30

Study results available
· View outcomes & findings →

Summary

International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis

Conditions

Interventions

DRUG

ponesimod

film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning

DRUG

teriflunomide

film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Tatiana Scherz, MD, PhD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-04
Primary Completion
2019-05-16
Completion
2019-05-16
FDA Drug
Yes

Countries

  • United States
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Canada
  • Croatia
  • Czechia
  • Finland
  • France
  • Georgia
  • Germany
  • Greece
  • Hungary
  • Israel
  • Italy
  • Latvia
  • Lithuania
  • Mexico
  • Poland
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02425644 on ClinicalTrials.gov